Which operation is best for Siewert type II stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial compares different surgical approaches for removing Siewert type II cancer at the esophagus–stomach junction. It aims to find which operation works best for people who can have the tumor removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed Siewert type II cancer at the esophagus–stomach junction (not type I or III).
- Your scans show the cancer has not spread to distant organs (no M0).
- Your tumor can be removed with either a specific keyhole operation or a specific Ivor Lewis endoscopic-assisted approach.
- If you have more locally advanced disease, you finished all planned chemotherapy (4 cycles of FLOT) before surgery.
- You are between 18 and 75 years old and can safely do surgery (heart/lung/liver/kidney function and blood counts meet limits).
- You can sign consent; you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two surgical approaches (right side of the chest vs. left side of the chest) for removing a certain type of cancer at the gastroesophageal junction. It aims to find which approach leads to better outcomes.
This study compares different ways to rebuild the digestive tract after removing the upper part of the stomach for cancer. It aims to find which method works best for eating and quality of life.
This trial compares two surgical techniques for treating a specific type of cancer at the junction of the stomach and esophagus. It aims to find which surgery offers better outcomes for patients.
This study tests a new robotic surgery system for a specific type of stomach-adjacent cancer. The goal is to see if the robotic approach is safe and effective in removing the tumor.
This trial compares two types of stomach-removing surgeries (total vs. partial gastrectomy) in people with a certain kind of advanced gastroesophageal junction cancer. The goal is to find out which surgery leads to better outcomes.
This trial compares a shorter course of chemo to the standard longer course after surgery, for people whose cancer was caught early and responded well to pre-surgery chemo. It aims to see if reducing chemo after surgery is just as effective with fewer side effects.
Hear when a new Siewert Type II Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.